Did you know that Cipla has the largest portfolio of respiratory products in the world?

Did you know that Cipla has the largest portfolio of respiratory products in the world?

For Cipla, the treatment of asthma is not just about its huge range of products, but also about educating both patients and medical practitioners about issues related to this disease.

Few conditions can be as frightening as experiencing breathing difficulties. Cipla also realised that patients need more than access to affordable and effective medication, but that they also need to understand what this disease is all about before they can effectively deal with it, and continue to lead productive lives.

“Asthma has become more common in both children and adults around the world in recent decades”, states the Report of the Global Initiative for Asthma (GINA). ‘It is estimated that asthma causes 346 000 deaths worldwide every year.’

But it has to be remembered that while asthma symptom prevalence has been decreasing in Europe, it has been increasing in Africa, Latin America, Eastern Europe and Asia, according to the GINA Report. Asthma is thought to affect more than 300 million people worldwide, but reliable comparison of reported prevalence isn’t easy, as there is not yet a universally accepted definition of asthma, says the Gina report.

Cipla has been at the forefront of innovation for inhalation therapy, and has brought relief not only to people in India, but across the world. The company has the world’s largest portfolio of inhalation products, which includes metered dose inhalers, dry powder inhalers, nasal sprays, nebulisers and a range of inhaled accessory devices.

Cipla Respiratory launched several inhalation products during 2015 in European markets and is developing critical new products for the US market.

But it is by no means all about medication: by means of its “BreatheFree” patient awareness and education programs across markets, the company is dedicated to making a difference to both patients and medical practitioners.

Here’s more about some of Cipla’s devices, many of which have transformed the lives of asthmatics:

  • Transparent Rotahaler is the world’s first transparent dry powder inhaler. These help to ensure consistent dose delivery.
  • Revolizer, exclusively developed by Cipla, is a novel single-dose capsule dry powder inhaler
  • Multi-haler is a multi-dose dry powder inhaler with an inbuilt dose counter
  • Autohaler is the first breath-actuated metered dose inhaler in India
  • Babymask and Infantmask are for the delivery of inhaled medications to young children. It is used with the Zerostat spacer
  • Nasal sprays for the treatment of nasal allergy
  • The widest range of dry powder Inhaler devices


In the interest of our patients, in accordance with SA law and our commitment to expertise, MediHub cannot subscribe to the practice of online diagnosis. Please consult a medical professional for specific medical advice. If you have any major concerns, please see your doctor for an assessment. If you have any cause for concern, your GP will be able to direct you to the appropriate specialists.


Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za